Exparel Use in Bilateral TAP Blocks for Postoperative Pain Control

• Status: Completed
• Trial end date: 2019-07-01
• Target enrollment: 0
• Participant gender: All

Summary

To determine if Exparel (Liposomal Bupivacaine, an FDA approved drug) use in ultrasound guided Transversus Abdominis Plane (TAP) blocks may reduce opioid requirement use postoperatively, reduce pain scores postoperatively, reduce incidence of nausea in the postop period, and decrease length of hospital stay

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: St. Luke's Hospital, Pennsylvania
• Treatments: Bupivacaine

Criteria

Inclusion Criteria:

• Women of Reproductive Potential

• Men of Reproductive Potential

• Minorities

• Healthy Controls/Volunteers

• Employees/Students

• Vulnerable populations (trauma victims, students > 18 yrs age, aged infirm, substance abusers, impoverished, terminally ill,)

patients of above inclusion criteria who 1) are not candidates of an neuraxial blockade (i.e. epidural) for postoperative pain control 2) who underwent a laparoscopic to open procedure intraoperatively

Exclusion Criteria:

• advanced dementia, not oriented to time or place

• advanced liver disease

• pregnant patients

• allergy to amide local anesthesia

• allergy to methemoglobinemia